Trial Profile
The protective effect of Telbivudine combined Radiotherapy for patients with primary liver cancer with hepatitis B virus infection.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2016
Price :
$35
*
At a glance
- Drugs Telbivudine (Primary)
- Indications Hepatitis B; Liver cancer
- Focus Therapeutic Use
- 21 May 2012 Planned End Date added from 31 Jan 2012 to 30 Apr 2012 as reported by Chinese Clinical Trial Register.
- 14 Dec 2010 New trial record